Oncology Times Broadcast News with the Audio Journal of Oncology

Scientific Editors: George Canellos, Dana-Farber Cancer Institute, Boston Gordon McVie, European Institute of Oncology, MilanPat Price, Christie Hospital, Manchester Gianni Bonadonna, Istituto Nazionale Tumori, Milan

REPORTING FROM: National Cancer Research Institute Cancer Conference, October 5-8, 2008, Birmingham, EnglandAmerican Society of Clinical Oncology Annual Meeting, May 30-June 3, 2008, Chicago, Illinois, Perspectives In Lung Cancer 9th European Congress, March 14-15, Torino, Italy

Sarah Maxwell and Peter Goodwin report on evidence that combining monoclonal antibodies with chemotherapy can extend life among patients with advanced non-small-cell lung cancer. Robert Pirker from the Medical University of Vienna tells Sarah Maxwell about his group's findings in the FLEX study using the epidermal growth factor receptor (EGF-R) inhibitor cetuximab; Christian Manegold from Heidelberg Universit, Manheim gives Peter Goodwin data on the vascular endothelial growth factor (VEGF-R) bevacizumab; while Giorgio Scagliotti from Torino University, Nick Thatcher from the Christie Hospital, Manchester and Howard Sandler from the University of Michigan, Ann Arbor discuss the clinical implications of these approaches to using molecular targeting to improve outcomes in advanced non-small-cell lung cancer. Michel Coleman from the London School of Hygiene and Tropical Medicine tells Peter Goodwin about the findings of the CONCORD study looking at international differences between survival rates for breast, prostate and colorectal cancers.